Search results
19 lut 2024 · In this study, we investigated whether weight loss and improved body composition were preserved better at 1 year after termination of active treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, supervised exercise program, or both combined for 1 year.
In this real-world cohort of over 2,400 patients with type 2 diabetes (baseline BMI 37 kg/m 2, HbA1c 8.5%), we found that initiation of a GLP-1 agonist (predominantly dulaglutide or liraglutide) without a structured behavioral intervention was associated with a 2% (~6 lbs) weight loss at 72 weeks.
25 wrz 2023 · Though traditionally used to treat diabetes and lower blood sugar levels, a class of medications called glucagon-like peptide 1 (GLP-1) agonists can also decrease appetite and promote...
9 maj 2015 · In addition to improving glycemic control, studies in patients with diabetes show that GLP-1 receptor agonists produce weight loss (3,4). This is an advantage, given that most people with type 2 diabetes are overweight or obese and many also find it difficult to lose weight.
Summary. Background The benefit of Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) in weight reduction against potential harms remains unclear. This study aimed at evaluating the bene fit-harm balance of initiating GLP-1 RAs versus placebo for weight loss in people living with overweight and obesity but without diabetes.
Compared with placebo treatments, GLP-1 agonists effectively reduce HbA1c and fasting plasma glucose levels [20]. Additionally, GLP-1 agonists are attractive options for patients with type 2 diabetes owing to their ability to lower HbA1c and weight while carry-ing a low risk for hypoglycemia.
6 cze 2023 · GLP‐1 RAs have also been shown to be effective for weight management and maintenance of weight loss in the treatment of people with overweight or obesity . Because absolute weight losses are greater for individuals without diabetes, trials included individuals with obesity, both with and without T2D.
